Continuous manufacturing μLOT® enabling technology could cut pharma industry’s use of toxic chemicals by one hundred times
Speaking at the ‘Innovative Chemistry for Peptide Manufacturing and Analysis’ conference, SB3000’s Chief R&D Officer Jens Bukrinski revealed that continuous manufacturing μLOT® technology could reduce the pharmaceutical industry’s use of toxic chemicals by 100 times.
Batch manufacturing has long been the standard for peptide pharmaceutical manufacturing, but it is hugely inefficient, requiring massive facilities and vast quantities of toxic raw materials. Peptide manufacture is also one of the most wasteful and least green chemical processes, and peptide synthesis is almost universally carried out in toxic solvents[i]. Typically, over 4000kg of toxic solvents are required to produce just one kilo of drug.
In contrast, innovative μLOT® continuous manufacturing enabling technology uses a chemical production line which can be constantly monitored in real time, uses just a tenth of the solvent required in batch processing and being modular is easily moved.
The FDA is actively encouraging a move to Continuous Manufacturing in the pharma industry. It has recognised that continuous manufacturing will reduce drug shortages, minimise batch manufacturing scale-up issues, and enable shorter process times, improve quality control, generate smaller footprints, and increased flexibility in scale[ii].
Jens commented during his presentation to the virtual ‘Innovative Chemistry for Peptide Manufacturing and Analysis’ conference, “μLOT® allows for continuous manufacturing of peptides at large scale, with hugely reduced environmental impact. For example, liraglutideiii is currently manufactured as a recombinant peptide in yeast. If manufactured synthetically with current batch SPPS it would generate 16,000 tons of toxic waste per year. Switching to continuous manufacturing using μLOT® would cut toxic waste by 100 times to just 160 tons toxic waste per year.”
He concluded, “As pressure mounts on the pharmaceutical industry to cut its use of toxic chemicals, the case for adopting μLOT® continuous manufacturing become indisputable.”
SB3000 is already engaged with a top ten pharma and working with a speciality pharma and the biotech Evaxion.
About SB3000 ApS
SB3000 ApS, which is based in Copenhagen, is dedicated to developing green manufacturing solutions for continuous manufacturing in the pharmaceutical industry and over the last few years has been developing its patented μLOT® solid phase, continuous manufacturing platform for the manufacture of peptide medicines.
Our technology addresses the growing threat of environmental damage by significantly reducing the amount of toxic solvents used in the production of medicines today and we are proud of our commitment to reduce the use of toxic solvents in peptide manufacturing by a 100 fold or more when comparing with current state of the art batch production.
Our ambitious plan is to expand the μLOT® technology into many other pharmaceutical manufacturing applications in the future.